Zhao L, et al. - This research entailed the contemplation of the safety and efficacy with regard to infarct-related artery (IRA) patency of prourokinase (proUK) injection within 6 h after symptom onset, in patients with ST-elevation myocardial infarction (STEMI). Such a fibrinolysis therapy was discovered to be efficient and safe, displaying a very low rate of bleeding complications. It served as an alternative treatment option for STEMI patients, particularly in scenarios where primary PCI could not be offered in a timely manner.

Methods

• The recrutiment consisted of 1,851 patients with acute myocardial infarction who received thrombolytic therapy with proUK.
• They were injected with 20 mg proUK intravenously followed by intravenous infusion of 30 mg proUK within 30 min.
• IRA was determined via coronary angiography at 120 min after thrombolysis.
• A scrutiny was conducted of the efficacy and safety of proUK thrombolysis in the eligible candidates.

Results

• The findings illustrated successful clinical reperfusion in 1,580 patients (85.4%).
• Marked reduction was noted in the number of leads with ST segment elevation and the amplitude of ST segment elevation within 24 h after thrombolytic therapy with proUK.
• Death was reported in 83 patients (4.48%) by the end of follow-up (7 days after thrombolysis).
• The incidences of post-infarction angina, re-infarction or reocclusion, and emergency revascularization were 15.2, 4.21, and 8.27%, respectively.
• Subcutaneous or mucosal bleeding was determined to be the most common bleeding complication.
• The incidence of intracranial hemorrhage was found to be 0.32%.